| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8826204 | Seminars in Nuclear Medicine | 2018 | 6 Pages |
Abstract
Over the past several decades, PET has emerged as critical to accurate staging and restaging of lymphomas. Nonetheless, a number of critical issues regarding its optimal use remain. Whereas risk-adapted strategies appear to improve the outcome of patients with Hodgkin lymphoma, results are less convincing in non-Hodgkin lymphoma. Assessment of metabolic tumor volume before treatment may permit novel induction strategies. New drugs that may induce an immune response may result in a false-positive FDG/PET scan, mandating modifications of current criteria to consider tumor flare reactions. Application of PET may be improved by integration of biomarker studies and a better understanding of the role of the microenvironment. Methods to improve the integration of FDG/PET enhance its role in the management of patients with lymphoma, leading to improved patient outcome.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Bruce D. Cheson,